Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the overlooked growth stocks to buy.
Amylyx Pharmaceuticals Inc. (AMLX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 8,952,365 | $121,662,640 | +14% | 3.51% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 6,816,828 | $92,640,693 | -23% | 0.15% |
| 3. | Saturn V Capital Management Xiaoying Tian | 4,604,878 | $62,580,292 | +42% | 13.72% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 4,075,478 | $55,385,746 | 2.7% | |
| 5. | Point72 Asset Management Steve Cohen | 2,790,066 | $37,916,998 | -39% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.45 | 8,100 | $100,845.00 | 63,100 | 2025-12-23 | Filing | |
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing | |
| $2.20 | 100,000 | $219,800.00 | 858,571 | 2024-09-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.83 | 1,974 | $27,299.04 | 3,379,465 | 2026-01-16 | Filing | |
| $13.59 | 136,193 | $1,850,794.77 | 3,378,621 | 2026-01-15 | Filing | |
| $13.89 | 1,995 | $27,701.17 | 3,379,398 | 2026-01-16 | Filing | |
| $13.58 | 136,193 | $1,849,868.66 | 3,378,546 | 2026-01-15 | Filing | |
| $11.11 | 3,326 | $36,953.86 | 177,104 | 2026-01-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 35,877 | $433,394 | 0% | |
| 2. | 21,645 | $261,472 | 0.01% | |
| 3. | 20,265 | $244,801 | 0.03% | |
| 4. | 5,337 | $64,471 | 0% | |
| 5. | 2,158 | $26,069 | 0% |
News See All
9 Overlooked Growth Stocks to Buy
On January 12, Victoria Greene, Founding Partner and CIO at G Squared Private Wealth, joined CNBC to discuss her current market outlook, selecting 'Fundamentals' as her word of the day.
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2025 Earnings Call Transcript
Operator: Good morning. My name is Carly, and I will be your conference operator today.
BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential.
Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
Known for speed, agility, and a high-risk, high-reward investment approach, Steve Cohen is one of the most successful hedge fund managers on Wall Street.
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX)
On August 8, 2025, H.C. Wainwright reaffirmed its ‘Buy’ rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) with a $16 price target.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
